Aprea Therapeutics Net Income Over Time
| APRE Stock | USD 0.69 0.06 8.00% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Aprea Therapeutics Performance and Aprea Therapeutics Correlation. Will Biotechnology sector continue expanding? Could Aprea diversify its offerings? Factors like these will boost the valuation of Aprea Therapeutics. If investors know Aprea will grow in the future, the company's valuation will be higher. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Aprea Therapeutics data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share (2.12) | Revenue Per Share | Quarterly Revenue Growth (0.99) | Return On Assets | Return On Equity |
Understanding Aprea Therapeutics requires distinguishing between market price and book value, where the latter reflects Aprea's accounting equity. The concept of intrinsic value—what Aprea Therapeutics' is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Market sentiment, economic cycles, and investor behavior can push Aprea Therapeutics' price substantially above or below its fundamental value.
Understanding that Aprea Therapeutics' value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Aprea Therapeutics represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. In contrast, Aprea Therapeutics' trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.
Cross Equities Net Income Analysis
Compare Aprea Therapeutics and related stocks such as Acurx Pharmaceuticals LLC, Biocardia, and Kiora Pharmaceuticals Net Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ACXP | (5.9 M) | (5.9 M) | (5.9 M) | (5.9 M) | (5.9 M) | (5.9 M) | (5.9 M) | (5.9 M) | (5.9 M) | (5.9 M) | (4.6 M) | (12.7 M) | (12.1 M) | (14.6 M) | (14.1 M) | (12.7 M) | (13.3 M) |
| BCDA | 135.6 K | 9.7 M | 305 K | 19 K | 234 K | 322 K | (10.3 M) | (12.3 M) | (14 M) | (14.7 M) | (15 M) | (12.6 M) | (11.9 M) | (11.6 M) | (7.9 M) | (7.2 M) | (6.8 M) |
| KPRX | (6 M) | (6 M) | (6 M) | (3.9 M) | (1.8 M) | (8.4 M) | (13.3 M) | (13.2 M) | (10.8 M) | (7.1 M) | (6.9 M) | (13.8 M) | (13.6 M) | (12.5 M) | 3.6 M | 3.2 M | 3.4 M |
| GLTO | (15.9 M) | (15.9 M) | (15.9 M) | (15.9 M) | (15.9 M) | (15.9 M) | (15.9 M) | (15.9 M) | (15.9 M) | (38.4 M) | (34.8 M) | (51.8 M) | (61.6 M) | (38.3 M) | (21.4 M) | (19.3 M) | (20.3 M) |
| ADIL | (818 K) | (818 K) | (818 K) | (818 K) | (818 K) | (818 K) | (420.2 K) | (1.1 M) | (11.6 M) | (8.6 M) | (10.9 M) | (19.4 M) | (12.7 M) | (7 M) | (13.2 M) | (11.9 M) | (12.5 M) |
| INAB | (2.1 M) | (2.1 M) | (2.1 M) | (2.1 M) | (2.1 M) | (2.1 M) | (2.1 M) | (2.1 M) | (2.1 M) | (5.1 M) | (8.6 M) | (14.7 M) | (27.4 M) | (30 M) | (30.4 M) | (27.4 M) | (26 M) |
| CELZ | 1.4 K | (24.1 K) | (25.6 K) | (27.3 K) | (28 K) | (30.8 K) | (766.1 K) | (2.7 M) | (13.7 M) | (8.5 M) | (36.3 M) | 19.2 M | (10.1 M) | (5.3 M) | (5.5 M) | (4.9 M) | (5.2 M) |
| HCWB | (7.3 M) | (7.3 M) | (7.3 M) | (7.3 M) | (7.3 M) | (7.3 M) | (7.3 M) | (7.3 M) | (7.3 M) | (7.3 M) | (5.8 M) | (12.9 M) | (14.9 M) | (25 M) | (30 M) | (27 M) | (25.7 M) |
| APVO | (53.3 M) | (53.3 M) | (53.3 M) | (53.3 M) | (51.1 M) | (59.3 M) | (112.4 M) | 7 M | (53.7 M) | (44.7 M) | (17.8 M) | (27.3 M) | 8 M | (17.4 M) | (24.1 M) | (27.7 M) | (29.1 M) |
| RNAZ | (453.4 K) | (453.4 K) | (453.4 K) | (453.4 K) | (453.4 K) | (453.4 K) | (453.4 K) | (453.4 K) | (453.4 K) | (607.2 K) | (2.3 M) | (6.8 M) | (17.6 M) | (18.5 M) | (16.8 M) | (15.1 M) | (14.3 M) |
Aprea Therapeutics and related stocks such as Acurx Pharmaceuticals LLC, Biocardia, and Kiora Pharmaceuticals Net Income description
Net income is one of the most important fundamental items in finance. It plays a large role in Aprea Therapeutics financial statement analysis. It represents the amount of money remaining after all of Aprea Therapeutics operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.My Equities
My Current Equities and Potential Positions
| Aprea Therapeutics | APRE |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Business Address | 3805 Old Easton |
| Exchange | NASDAQ Exchange |
USD 0.69
Check out Aprea Therapeutics Performance and Aprea Therapeutics Correlation. For information on how to trade Aprea Stock refer to our How to Trade Aprea Stock guide.You can also try the Idea Analyzer module to analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas.
Aprea Therapeutics technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.